Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.

@article{Tadori2008CharacterizationOA,
  title={Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.},
  author={Yoshihiro Tadori and Robert A. Forbes and R. D. Mcquade and Tetsuro Kikuchi},
  journal={European journal of pharmacology},
  year={2008},
  volume={597 1-3},
  pages={
          27-33
        }
}
Aripiprazole is the first dopamine D2/D3 receptor partial agonist approved for use in the treatment of psychiatric disorders, including schizophrenia, bipolar disorder, and unipolar depression in the US. To explore the functional activity of aripiprazole at dopamine D3 receptors, we established Chinese hamster ovary (CHO) cell lines stably expressing high and low densities of Ser-9 and Gly-9 variants of human dopamine D3 receptors and compared aripiprazole's dopamine D3 pharmacological… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Current drug treatments targeting dopamine D3 receptor.

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania

VIEW 1 EXCERPT
CITES BACKGROUND

Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.

VIEW 1 EXCERPT
CITES BACKGROUND